I am pleased to announce our latest round of speakers for the Fierce Biotech Virtual Event Next Gen. To view this email as a web page,
click here | | Dear E, I am pleased to announce our latest round of speakers for the Fierce Biotech Virtual Event Next Gen: What’s beyond the leading edge of biotech and pharma? This series will run virtually June 22-23, 2021.
Join speakers from Novartis, Genentech, Allogene, Bristol Meyers Squibb, LEXEO Therapeutics, AstraZeneca and more for a series of CEO interviews and panel discussions exploring new waves of cancer targets, novel approaches to cell and gene therapies, cutting-edge technologies set to change biopharma manufacturing and a panel discussion around diversity in the biopharma industry. With a strong focus on networking, this year's virtual platform will allow you to facilitate one-to-one video meetings and group chats with speakers, partners, and attendees. | |
|
|
| | | Dave Lennon
Novartis Gene Therapies
President | | R. Nolan Townsend
LEXEO Therapeutics
CEO | | Kristen Hege
Bristol Myers Squibb
SVP - Early Clinical Development, Oncology/Hematology and Cell Therapy |
|---|
|
| |
|
|
| | | Bobby Gaspar, M.D., Ph.D
Orchard Therapeutics
Co-Founder and CEO | | Eric Rubin, M.D.
Merck Research Labs
SVP & Therapeutic Area Head, Oncology Early Development | | Pearl Huang
Cygnal Therapeutics
CEO |
|---|
|
| |
|
|
| | | Shankar Ramaswamy, M.D.
Kriya Therapeutics
Co-Founder and CEO | | Alison Moore, Ph.D
Allogene
Chief Technical Officer | | Camille Hertzka
AstraZeneca
Head of Medical Affairs, US Oncology |
|---|
|
| |
|
|
| | Thank You to Our Sponsors | |
|
|
| | | You are currently subscribed as [email protected]
If you no longer wish to receive promotions from Fierce Healthcare, simply unsubscribe.
Refer to our Privacy Policy.
Fierce Life Sciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017
© 2021 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission. |
| |
|
|
|
